Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

edlund_mark_1000x714_ENV

Mark Edlund

Associate

New York +1 212 841 1284

  • About
  • Representative Matters
  • Credentials
  • About

    Mark advises public and private companies and the financial institutions with which they work in a broad range of capital markets transactions. He also helps public companies in preparing all major Securities Act and Exchange Act forms and in complying with beneficial ownership reporting and stock exchange compliance. Mark has particular experience working on matters in the life sciences industry and with foreign private issuers.

    In particular, Mark counsels on:

    • initial public offerings;
    • follow-on offerings, including registered direct offerings and so-called “bought deals;”
    • at-the-market offerings and equity lines of credit;
    • rights offerings;
    • transactions exempt from registration under the Securities Act, such as offerings under Rule 144A, Regulation D, and Regulation S; and
    • preparing Forms S-1, S-3, S-4, S-8, F-1, F-3, F-4, F-6, 8-A, 10-K, 10-Q, 8-K, 20-F, and 6-K, proxy statements, and the various beneficial ownership reporting forms and schedules.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • The underwriters on Immatics N.V.’s $110 million follow-on offering of ordinary shares.
    • Selecta Biosciences, Inc. on its $38.7 million follow-on offering of common stock and warrants.
    • The sales agents in more than a dozen at-the-market offering programs.
    • BioNTech SE on its initial public offering and $512 million rights offering.
    • The underwriter on Roivant Sciences Ltd.’s $150 million follow-on offering of common shares.
    • The investor in committed equity facilities for several special purpose acquisition companies (SPACs) and post-de-SPAC operating companies.
    • The initial purchaser on Kadmon Holdings, Inc.’s $200 million convertible notes offering.
    • The underwriters on Trevi Therapeutics, Inc.’s initial public offering.
    • The underwriters on several follow-on offerings for RedHill Biopharma Ltd.
    • The underwriters on several follow-on offerings for Zosano Pharma Corporation.

    Areas of Expertise

  • Credentials
    Education
    • Washington University School of Law, J.D., 2018
        • cum laude
    • University of Michigan, B.A., 2015
    Bar Admissions
    • New York

    Areas of Expertise

News and Insights

Events